ValiRx PLC - Nuneaton, England-based life sciences company focused on early-stage cancer therapeutics - Signs agreement with Dundee University's drug discovery unit to access research concerning novel therapeutic candidates. The agreement will be active for a period of five years, in which ValiRx may review research projects from the unit in areas aligned with the company's focus on cancer therapeutics.
Chief Executive Officer Suzy Dilly said: "We are delighted to be able to streamline the process of reviewing and accessing the excellent research from University of Dundee's drug discovery unit, which will help to bring on evaluation projects more quickly. The strength of the drug discovery unit, and research facilities at Dundee are very impressive and, having reviewed multiple projects from teams there over the past year, we believe that this evaluation agreement will be the first of a series of new projects that can be brought into our pipeline."
Current stock price: 4.82 pence per share, up 2.6% in London on Monday morning
12-month change: down 51%
By Hugh Cameron, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2024 Alliance News Ltd. All Rights Reserved.
ValiRx (VAL)